American College of Clinical Pharmacy
      Search      Cart
         

BCACP and BCGP Clinical Session -- How Low Do You Go? Applying the 2018 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines to Individual Patients

Monday, October 28, 2019 from 8:30 AM to 9:30 AM EST at 2nd Floor: Beekman/Sutton North

Available for 1.00 hours of CPE credit
Activity Number: 0204-9999-19-270-L01-P
Activity Type: An Application-Based Activity

The BCACP and BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified ambulatory care pharmacists and board-certified geriatric pharmacists, approved by the Board of Pharmacy Specialties and cosponsored by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP and BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and then must pass the associated posttest. Access to the BCACP or BCGP Clinical Sessions posttests will be available on December 17, 2019 at www.accp.com/myaccount to anyone who has purchased access to the BCACP or BCGP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 29, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be June 17, 2020.

Speakers
  • Eric J. MacLaughlin, Pharm.D., FASHP, FCCP, BCPSSpeaker: Eric J. MacLaughlin, Pharm.D., FASHP, FCCP, BCPS
    Professor and Chair, Department of Pharmacy Practice Professor, Departments of Family Medicine and Internal Medicine Texas Tech University Health Sciences Center, Amarillo, Texas
      View Biography


Learning Objectives
1. Compare and contrast the therapeutic goals in the 2013 and 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for management of blood cholesterol.
2. Evaluate a patient’s risk of cardiovascular disease using traditional means and taking into consideration “risk-enhancing factors”.
3. Design patient-centered cholesterol treatment plans in complex patients with dyslipidemia.